Drug Development

dystrophin
Blog Post

Simply Stated: What is Duchenne Muscular Dystrophy?

By Sujatha Gurunathan | February 16, 2022
Blog Post

FDA Approves argenx’s Vyvgart for Treatment of gMG

By Sujatha Gurunathan | December 20, 2021
Featured Article

Demystifying Drug Prices

By Larry Luxner | November 19, 2021
Blog Post

Clinical Trial Alert: Early Phase Study of SRP-9001 in Boys with DMD

By Sujatha Gurunathan | November 9, 2021
Blog Post

Clinical Trial Alert: Phase 2/3 Study of Tideglusib (AMO-02) in Children and Adolescents with Congenital Myotonic Dystrophy

By Sujatha Gurunathan | November 9, 2021
Blog Post

Muscular Dystrophy Association Awards 18 Grants Totaling Over $1.6 Million for Neuromuscular Disease Research

By Sujatha Gurunathan | November 5, 2021
Blog Post

Clinical Trial Alert: Phase 3b Study of Oral Edaravone in Adults with ALS

By Sujatha Gurunathan | October 11, 2021
Blog Post

Capricor Announces Positive Results from its Phase 2 Study of CAP-1002 to Treat DMD

By Sujatha Gurunathan | September 30, 2021
Blog Post

Clinical Trial Alert: Phase 2 Study of Ataluren in Children with Nonsense Mutation DMD

By MDA Staff | September 20, 2021
Blog Post

Clinical Trial Alert: Phase 3 Study of High Dose Eteplirsen in Boys with DMD

By MDA Staff | September 20, 2021